RecruitingPhase 3

Nicorandil as Anti-inflammatory in Rheumatoid Arthritis

Egypt46 participantsStarted 2024-11-01

Plain-language summary

This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) i.e., 28 joints disease activity score (DAS-28) \>2.6. * Patients receiving the conventional DMARDs Exclusion Criteria: * Patients with heart disease (congestive heart failure, arrhythmia and ischemic heart disease), diabetes, active infection, and other illness except rheumatoid arthritis. * Patients with severe renal and hepatic dysfunction. - Patients receiving biological DMARDs. * Patients receiving oral prednisolone greater than 15mg/day. * Patients with hypersensitivity to study medications. * Patients using antioxidants. * Pregnant and lactating females.

What they're measuring

change in 28-joint count Disease Activity Score (DAS28) using C- reactive protein level (CRP)

Timeframe: 3 months

change in Multidimensional Health Assessment Questionnaire (MDHAQ) scores.

Timeframe: 3 months

Trial details

NCT IDNCT07516769

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-03

Contact for this trial

Karim Abu Elfath Hussein

+201141332986 Kareem_hussein@pharm.tanta.edu.eg

View on ClinicalTrials.gov More Rhumatoid Arthisis trials